2-(1-Azabicyclo[2.2.2]octan-3-yl)-1-benzothiophene 1,1-dioxide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 英文名称: 2-(1-Azabicyclo[2.2.2]octan-3-yl)-1-benzothiophene 1,1-dioxide
• 化学式: C₁₅H₁₇NO₂S
• 分子量: 275.4
• InChiKey: MAUYSDWZUSEXQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Novel compounds, their preparation and use
  申请人：——

  公开号：US20040180877A1

  公开（公告）日：2004-09-16

  The present invention relates to novel compounds that are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及新型化合物，它们是烟碱乙酰胆碱受体的胆碱能配体以及单胺受体和转运体的调节剂。 由于其药理特性，本发明化合物可用于治疗各种疾病或紊乱，如与中枢神经系统（CNS）、周围神经系统（PNS）的胆碱能系统有关的疾病或紊乱、与平滑肌收缩有关的疾病或紊乱、内分泌疾病或紊乱、与神经变性有关的疾病或紊乱、与炎症有关的疾病或紊乱、疼痛以及终止滥用化学物质引起的戒断症状。
• NOVEL COMPOUNDS, THEIR PREPARATION AND USE
  申请人：NEUROSEARCH A/S

  公开号：EP1406900A1

  公开（公告）日：2004-04-14
• US7314870B2
  申请人：——

  公开号：US7314870B2

  公开（公告）日：2008-01-01
• [EN] NOVEL COMPOUNDS, THEIR PREPARATION AND USE<br/>[FR] NOUVEAUX COMPOSES, PREPARATION ET UTILISATION DE CES DERNIERS
  申请人：NEUROSEARCH AS

  公开号：WO2003004493A1

  公开（公告）日：2003-01-16

  The present invention relates to novel compounds that are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.